BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Muñoz AE, Pollarsky FD, Marino M, Cartier M, Vázquez H, Salgado P, Romero G. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy. World J Gastroenterol 2021; 27(28): 4639-4652 [PMID: 34366626 DOI: 10.3748/wjg.v27.i28.4639]
URL: https://www.wjgnet.com/1007-9327/full/v27/i28/4639.htm
Number Citing Articles
1
Mohan Chandra Vinay Bharadwaj Gudiwada, Vinuthna Gaddam, Maheen Rahman, Jaswanth R Jasti, Paritaben Bhalodia, Sahas Reddy Jitta. High-Intensity Statin Therapy and Associated Rhabdomyolysis in Chronic Liver Disease: A Case Report and Review of LiteratureCureus 2023;  doi: 10.7759/cureus.39150
2
Maxime Mallet, Cristina Alina Silaghi, Philippe Sultanik, Filomena Conti, Marika Rudler, Vlad Ratziu, Dominique Thabut, Raluca Pais. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosisHepatology 2023;  doi: 10.1097/HEP.0000000000000456
3
Andrew S. Bell, Emma M. O’Connell, Falk W. Lohoff. Cholesterol2022; : 747 doi: 10.1016/B978-0-323-85857-1.00036-5
4
Mar Gil, Lareen Khouri, Imma Raurell, Diana Rafael, Fernanda Andrade, Ibane Abasolo, Simo Schwartz, María Martínez-Gómez, María Teresa Salcedo, Juan Manuel Pericàs, Diana Hide, Mingxing Wei, Norman Metanis, Joan Genescà, María Martell. Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial CellsPharmaceutics 2023; 15(10): 2463 doi: 10.3390/pharmaceutics15102463
5
Spencer R Goble, Philippe Nyembo, Holly Rodin, George Konstantinides, Jesse Powell, Amanda J Noska. Statin Utilization Among Individuals Infected With Hepatitis C Virus: A Retrospective Cohort StudyCureus 2023;  doi: 10.7759/cureus.36049
6
文瑾 程. New Advances in the Treatment of Portal Hypertension and Its Complications in CirrhosisAdvances in Clinical Medicine 2022; 12(03): 2192 doi: 10.12677/ACM.2022.123316
7
John P. ONeill, Cathal S Clifford, Niamh P. Nolan, P. Aiden McCormick. Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosisIrish Journal of Medical Science (1971 -) 2023; 192(4): 1657 doi: 10.1007/s11845-022-03153-0
8
Carlos Sanz-Garcia, Yulia A. Nevzorova, Eduardo Martínez-Naves, Francisco Javier Cubero, Alejandro Hionides-Gutierrez, Jose Ramón Sañudo, Carlos Enrich, Carles Rentero, Pau Sancho-Bru, Ricardo U. Macías-Rodriguez, Astrid Ruiz-Margain, David Kershenobich-Stalnikowitz, Nestor R. Vargas, Alberto E. Muñoz, Helder I. Nakaya. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver CirrhosisGastroenterología y Hepatología (English Edition) 2023; 46(4): 322 doi: 10.1016/j.gastre.2022.05.010
9
Irina Gîrleanu, Anca Trifan, Laura Huiban, Cristina Muzîca, Oana Cristina Petrea, Ana Maria Sîngeap, Camelia Cojocariu, Stefan Chiriac, Tudor Cuciureanu, Irina Iuliana Costache, Carol Stanciu. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to InjuryLife 2022; 12(7): 1036 doi: 10.3390/life12071036
10
Sara Armani, Andreas Geier, Thomas Forst, Uta Merle, David H. Alpers, Martin W. Lunnon. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactionsBritish Journal of Clinical Pharmacology 2024; 90(4): 942 doi: 10.1111/bcp.15990
11
Carlos Sanz-Garcia, Yulia A. Nevzorova, Eduardo Martínez-Naves, Francisco Javier Cubero, Alejandro Hionides-Gutierrez, Jose Ramón Sañudo, Carlos Enrich, Carles Rentero, Pau Sancho-Bru, Ricardo U. Macías-Rodriguez, Astrid Ruiz-Margain, David Kershenobich-Stalnikowitz, Nestor R. Vargas, Alberto E. Muñoz, Helder I. Nakaya. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver CirrhosisGastroenterología y Hepatología 2023; 46(4): 322 doi: 10.1016/j.gastrohep.2022.05.012
12
R. M. Lupachev, M. L. Maksimov. The use of statins and inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK 9) in patients with dyslipidemiaGlavvrač (Chief Medical Officer) 2024; (1): 20 doi: 10.33920/med-03-2401-02